PIA Executive Committee:
Immunity and Neurodegeneration
Chair: Donna Wilcock, PhD
Dr. Wilcock is an Associate Professor at the University of Kentucky Sanders-Brown Center on Aging. Dr. Wilcock’s research lab is interested in vascular cognitive impairment and dementia; with projects to examine the molecular mechanisms of vascular cognitive impairment, focusing primarily on inflammatory processes. Dr. Wilcock also have projects that determine the influence cerebrovascular disease has on the progression and severity of Alzheimer's disease, as well as how these vascular pathologies affects response to Alzheimer's disease targeted therapeutics. Finally, in collaboration with Elizabeth Head of Pharmacology and Frederick Schmitt of Neurology to assess neuroinflammatory changes in Down Syndrome, we are developing a translational research program examining neuroinflammatory proteins and homocysteine as modifiable biomarkers of cognitive impairment due to both Alzheimer's disease and cerebrovascular pathologies.
Vice Chair: Andrea Tenner, PhD
Dr. Andrea Tenner is currently Professor of Molecular Biology & Biochemistry, Neurobiology & Behavior, and Pathology & Laboratory Medicine at the University of California, Irvine. After earning her Ph.D. at the University of California, San Diego, Dr. Tenner entered the complement field as a postdoctoral fellow at Scripps Research Foundation in La Jolla. She has made major contributions to how this innate immune system influences protective responses to pathogens and injury, modulates immune responses, contributes to neuroprotection and, when dysregulated, causes detrimental inflammatory disorders particularly in neurodegenerative diseases such as Alzheimer’s disease. Her laboratory has explored the consequences of activation of the entire complement pathway by fibrillar (ß-sheet) amyloid plaques in Alzheimer’s disease, including the contribution of complement activation product C5a to inflammation and progression of Alzheimer’s disease in mouse models. A major focus of her lab today is to identify and verify potential targets to slow or stop progression of this and other neurodegenerative diseases using genetic, molecular, confocal microscopy and behavioral approaches. Another current focus is on neuroprotection and potential therapeutic targets to enhance neuron survival and function. In addition, she is Co-Director of UCI’s MODEL-AD group, with the goal of generating new mouse models that mimic sporadic (late onset) AD.
Programs Chair: Marcia Gordon, PhD
Marcia N. Gordon, PhD is a Professor of Translational Science and Molecular Medicine at Michigan State University. Dr. Gordon has been involved in Alzheimer’s research for over 25 years. Her research program, funded by nationally competitive federal grants, foundation grants and corporate contracts, is focused on preclinical biomedical laboratory research using mouse models. She is especially interested in the role of innate immunity in neurodegenerative disease, biochemical and cellular changes accompanying aging, and mechanisms of resilience and neuroprotection, with the ultimate goal of developing novel, disease-modifying therapeutics for Alzheimer’s disease, including small molecule agents, vaccines and biologics. Dr. Gordon has published over 100 scientific articles, and is a past recipient of the Zenith Award from the Alzheimer’s Association. She is proud to have mentored numerous high school, undergraduate, graduate and postdoctoral scholars, and is a diligent proponent for women in the sciences. Dr. Gordon has served on the Immunity and Neurodegeneration PIA Executive Committee, and as Chair of the Program Committee for the PIA Day Program at the Alzheimer’s Association International Conference since 2015.
Communications Chair: Brianne Bettcher, PhD
Dr. Bettcher is an Assistant Professor and neuropsychologist at the University of Colorado Anschutz Medical Campus, and she directs neuropsychology research at the Rocky Mountain Alzheimer’s Disease Center. She obtained a PhD from Temple University in Clinical Psychology with a specialization in Neuroscience, and she completed her fellowship at the University of California San Francisco’s Memory and Aging Center. The goal of Dr. Bettcher’s research program is to elucidate modifiable, immune-mediated factors that will inform early treatments for cognitive decline for a wide range of neurodegenerative diseases. Her laboratory utilizes plasma-based and CSF-based multiplex arrays of chemokines, growth factors, and cytokines to delineate how peripheral innate immune signatures contribute to pathological aging trajectories. Her work also focuses on immune interactions between the periphery and the central nervous system.
Steering/Executive Committee: Delphine Boche, PhD
Delphine Boche is a Professor of Neuroimmunopathology within The faculty of Medicine at the University of Southampton. Her research focuses on understanding neuroinflammation and its consequences in patients affected by neurological disease. She was the recipient of a European Marie Curie Individual Fellowship (2000) and of a MRC New Investigator Award (2006).
Her main interest is to develop a greater understanding of the role of neuroinflammation in relation with ageing, neurological diseases and systemic inflammation, using the complementary approaches of human brain analysis and animal models. Her work is located at the junction between clinical neurodegenerative disease, human neuropathology and experimental neuroscience where she has developed expertise in clinical neuroimmunopathology.
Steering/Executive Committee: Guillaume Dorothee, PhD
Dr. Guillaume Dorothée is a tenured Senior Investigator in neuroimmunology at the French National Institute of Health and Medical Research (INSERM) and team leader at the Saint-Antoine Research Center in Paris, France. He obtained his Ph.D in Immunology from University Pierre and Marie Curie (Paris 6) in 2003, and trained as a postdoctoral fellow in antimicrobial immunity at Memorial Sloan-Kettering Cancer Center in New York, and in fundamental immunology at the Curie Institute in Paris. Since 2007, his research focuses on understanding the role of neuroimmune interactions in the pathophysiology of Alzheimer’s disease (AD) and other neurodegenerative disorders, and developing innovative immunotherapy approaches and immune-based biomarkers in such conditions. Based on a translational research approach in mouse models and clinical studies, one focus of Dr. Dorothée’s laboratory addresses the interplay between peripheral adaptive immunity and innate neuroinflammation in Alzheimer’s disease and related disorders. The team’s works in mouse models of AD-like amyloid and Tau pathology suggest that different T cell populations may contribute to modulate AD progression, in part by modulating innate neuroinflammatory responses. The studies further highlight the therapeutic potential in AD of T-cell-targeting peripheral immunomodulatory approaches for rebalancing detrimental innate neuroinflammation. The team’s clinical works strengthen the potential interest of such approaches in patients with AD, and further support an instrumental role of other peripheral immune populations in AD pathophysiology, including neutrophils as key effectors of innate immunity. Dr. Dorothée is a Scientific Council member of Association France Alzheimer, Executive Committee member of the French Club for NeuroImmunology (CFNI), and Expert Evaluator for the European Commission.
Steering/Executive Committee: Christopher Norris, PhD
Chris Norris is a Professor and Associate Director of Research and Faculty Advancement at the University of Kentucky Sanders-Brown Center on Aging (SBCoA). He received his PhD in Neuroscience from the University of Virginia in 1998, working in the lab of Dr. Tom Foster. His dissertation research showed that hippocampal synapses in aged rats were more susceptible to activity-dependent depression arising from Ca2+ dysregulation and elevated protein phosphatase activity: a finding that has been subsequently demonstrated in numerous injury and disease models characterized by learning and memory deficits. His work as a postdoctoral fellow in Dr. Phil Landfield’s laboratory at the University of Kentucky found that Ca2+-dysregulation and elevated phosphatase activity are not only intimately linked, but form a deleterious positive feedback cycle in aging brain. These investigations led to the unexpected discovery that astrocytes are a focal point of hyperactive Ca2+-dependent phosphatase (calcineurin) activity, highlighted by the intense upregulation of calcineurin in activated astrocytes of aging wild-type mice and transgenic APP/PS1 mice—especially in the immediate vicinity of amyloid deposits. After joining the faculty at the SBCoA in 2004, the Norris lab has investigated the impact of astrocyte activation, and hyperactive calcineurin signaling, on the progression of Alzheimer’s pathophysiology using both human postmortem brain specimens and mouse models of amyloidosis. Experimental approaches commonly used in the Norris lab include: electrophysiology, multiphoton imaging, AAV-mediated gene delivery, protein biochemistry, gene expression analysis, and small rodent behavioral assessment. An ongoing R01 project, funded since 2006, has revealed key causative roles of astrocytic calcineurin/NFAT signaling on neuroinflammation, glutamate dysregulation, and synapse dysfunction associated with Alzheimer’s pathology and small cerebrovessel disease.
Adhoc Member: Richard Margolin, MD
Dr. Margolin's biography is coming soon.
Student Trainee: Brittani R. Price
Brittani R. Price is currently a post-doctoral research fellow at Brigham Women's Hospital and Harvard Medical School under the mentorship of Dr. Cynthia Lemere. She completed her bachelor's degree in biomedical science at Morehead State University in 2015 and her doctoral work under the mentorship of Dr. Donna Wilcock at the Sanders-Brown Center on Aging in 2019. Her graduate work focused on molecular mechanisms underlying vascular cognitive impairment and dementia as well as preclinical therapeutic targeting of TREM2 for the treatment of Alzheimer's disease. Brittani is now focused on preclinical therapeutic targeting of post-translationally modified forms of amyloid and the prevention of adverse cerebrovascular events following immunotherapy.
Immediate Past Chair: Bruce Lamb, PhD
Dr. Lamb received a BA degree in Biology from Swarthmore College, his PhD in Molecular Biology from the University of Pennsylvania and a post-doctoral fellowship at Johns Hopkins University. In 1996, Dr. Lamb was recruited to Case Western Reserve University, where he rose from Assistant to Associate Professor and finally moved to the Cleveland Clinic in 2005. At the Cleveland Clinic, Dr. Lamb was promoted from Associate Professor to Full Professor in 2011, and later was recruited to become the Executive Director of the Stark Neurosciences Research Institute with the IU School of Medicine in January 2016.
Dr. Lamb has received numerous awards and honors including the Jennifer B. Langston Award from the Cleveland Chapter of the Alzheimer’s Association, the National Civic Award, and the Zaven Khachaturian Lifetime Achievement Award from the National Alzheimer’s Association. He is a Fellow in the American Association for the Advancement of Science and a member (and Vice-Chair) of the Medical and Scientific Advisory Council of the National Alzheimer’s Association.
Dr. Lamb’s laboratory works on the basic science of Alzheimer’s disease, with a focus on: 1) genetic modifiers identified from both mouse and human studies, 2) microglia and neuronal-microglial communication in the development and progression of AD pathologies; and 3) traumatic brain injury as an environmental modifier for the development of AD pathologies. Dr. Lamb is also one of the lead PIs of the NIH-funded Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD) consortium. In addition, Dr. Lamb is actively involved in advocacy for increased research funding for the disease.